Abrogation of postprandial triglyceridemia with dual PPAR α/γ agonist in type 2 diabetes mellitus: a randomized, placebo-controlled study

Ashu Rastogi,Richard L. Dunbar,Hemant P Thacker,Jayesh Bhatt,Krupi V. Parmar,Deven V. Parmar

Abrogation of postprandial triglyceridemia with dual PPAR α/γ agonist in type 2 diabetes mellitus: a randomized, placebo-controlled study

2020

Ashu Rastogi
Richard L. Dunbar
Hemant P Thacker
Jayesh Bhatt
Krupi V. Parmar
Deven V. Parmar

Aims Lowering postprandial lipemia may mitigate cardiovascular risk in patients with diabetic dyslipidemia. This study was aimed to investigate whether saroglitazar suppresses postprandial lipemia in patients with diabetes and dyslipidemia.

Keywords:

Endocrinology
Internal medicine
Dyslipidemia
Medicine
Diabetes mellitus
Agonist
Postprandial
Type 2 Diabetes Mellitus
Saroglitazar
Triglyceride
Placebo-controlled study
Metformin
Gastroenterology
Area under the curve
Placebo

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations